|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
|
EP0028683A1
(en)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotic C-15003 PHO and production thereof
|
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
|
US4737462A
(en)
|
1982-10-19 |
1988-04-12 |
Cetus Corporation |
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
|
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
|
DE3689123T2
(de)
|
1985-11-01 |
1994-03-03 |
Xoma Corp |
Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
|
|
US4880935A
(en)
|
1986-07-11 |
1989-11-14 |
Icrf (Patents) Limited |
Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
IL106992A
(en)
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Acylhydrazone derivatives of anthracycline and methods for their preparation
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5362852A
(en)
|
1991-09-27 |
1994-11-08 |
Pfizer Inc. |
Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
US6080560A
(en)
|
1994-07-25 |
2000-06-27 |
Monsanto Company |
Method for producing antibodies in plant cells
|
|
US5855887A
(en)
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
DK0871490T3
(da)
|
1995-12-22 |
2003-07-07 |
Bristol Myers Squibb Co |
Forgrenede hydrazonlinkere
|
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド |
免疫療法のｃｔｌａ−４結合ペプチド
|
|
US6512162B2
(en)
|
1998-07-10 |
2003-01-28 |
Calgene Llc |
Expression of eukaryotic peptides in plant plastids
|
|
US20030167531A1
(en)
|
1998-07-10 |
2003-09-04 |
Russell Douglas A. |
Expression and purification of bioactive, authentic polypeptides from plants
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
CZ302706B6
(cs)
|
1998-12-23 |
2011-09-14 |
Pfizer Inc. |
Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
BR0014945A
(pt)
|
1999-10-21 |
2004-08-31 |
Monsanto Co |
Modificação pós-traducional de proteìnas recombinantes produzidas em plantas
|
|
JP2003520828A
(ja)
|
2000-01-27 |
2003-07-08 |
ジェネティクス インスティテュート，エルエルシー |
Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
WO2003062176A1
(en)
|
2002-01-23 |
2003-07-31 |
Johnson Matthey Plc |
Sulphided ion exchange resins
|
|
DK1545613T3
(da)
|
2002-07-31 |
2011-11-14 |
Seattle Genetics Inc |
Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
|
|
BRPI0315295C1
(pt)
|
2002-10-17 |
2021-05-25 |
Genmab As |
anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
|
|
CA2508831C
(en)
|
2002-12-13 |
2012-05-01 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
|
JP5356648B2
(ja)
|
2003-02-20 |
2013-12-04 |
シアトル ジェネティックス， インコーポレイテッド |
抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
CA2541651C
(en)
|
2003-10-22 |
2011-05-24 |
Keck Graduate Institute |
Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
|
|
EP2478912B1
(en)
|
2003-11-06 |
2016-08-31 |
Seattle Genetics, Inc. |
Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
|
|
JP4942643B2
(ja)
|
2004-03-02 |
2012-05-30 |
シアトル ジェネティックス， インコーポレイテッド |
部分的に付加された抗体およびそれらの結合体化方法
|
|
SI1674111T1
(sl)
*
|
2004-07-09 |
2011-02-28 |
Chugai Pharmaceutical Co Ltd |
Protitelo proti glipikanu 3
|
|
DK1791565T3
(en)
|
2004-09-23 |
2016-08-01 |
Genentech Inc |
Cysteingensplejsede antibodies and conjugates
|
|
ES2708763T3
(es)
|
2005-07-07 |
2019-04-11 |
Seattle Genetics Inc |
Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
|
|
US20070087005A1
(en)
*
|
2005-10-14 |
2007-04-19 |
Lazar Gregory A |
Anti-glypican-3 antibody
|
|
WO2007137170A2
(en)
*
|
2006-05-20 |
2007-11-29 |
Seattle Genetics, Inc. |
Anti-glypican-3 antibody drug conjugates
|
|
PT2099823E
(pt)
|
2006-12-01 |
2014-12-22 |
Seattle Genetics Inc |
Agentes de ligação ao alvo variantes e suas utilizações
|
|
DK2265283T3
(da)
|
2008-03-18 |
2014-10-20 |
Seattle Genetics Inc |
Auristatin-lægemiddel-linker-konjugater
|
|
WO2010081004A1
(en)
|
2009-01-09 |
2010-07-15 |
Seattle Genetics, Inc. |
Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
|
|
ES3000111T3
(en)
|
2009-02-13 |
2025-02-27 |
Immunomedics Inc |
Intermediates for preparing conjugates with an intracellularly-cleavable linkage
|
|
SG10201810743WA
(en)
|
2009-06-03 |
2018-12-28 |
Immunogen Inc |
Conjugation methods
|
|
CA2799540A1
(en)
|
2010-06-08 |
2011-12-15 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
|
MX347954B
(es)
|
2010-09-29 |
2017-05-19 |
Agensys Inc |
Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
|
|
BR112013027119A8
(pt)
|
2011-04-21 |
2018-03-06 |
Seattle Genetics Inc |
novos conjugados ligante-droga (adcs) e uso dos mesmos
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
ES2773710T3
(es)
|
2012-10-11 |
2020-07-14 |
Daiichi Sankyo Co Ltd |
Enlazadores para conjugados de anticuerpo - fármaco
|
|
EP3564259A3
(en)
|
2012-11-09 |
2020-02-12 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
|
WO2015057066A1
(en)
|
2013-10-14 |
2015-04-23 |
Synaffix B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
|
NZ758049A
(en)
|
2013-10-15 |
2024-03-22 |
Seagen Inc |
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
|
|
KR102442906B1
(ko)
|
2013-12-19 |
2022-09-14 |
씨젠 인크. |
표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커
|
|
CA2937753A1
(en)
|
2014-02-17 |
2015-08-20 |
Seattle Genetics, Inc. |
Hydrophilic antibody-drug conjugates
|
|
EP4148138A1
(en)
|
2014-08-04 |
2023-03-15 |
SynAffix B.V. |
Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
|
|
FI3900742T3
(fi)
|
2014-09-11 |
2024-08-16 |
Seagen Inc |
Tertiääristä amiinia sisältävien lääkeaineiden kohdennettu antaminen
|
|
SG11201701128YA
(en)
|
2014-09-12 |
2017-03-30 |
Genentech Inc |
Cysteine engineered antibodies and conjugates
|
|
WO2016102679A1
(en)
|
2014-12-23 |
2016-06-30 |
Nbe-Therapeutics Ag |
Binding protein drug conjugates comprising anthracycline derivatives
|
|
KR20180090290A
(ko)
|
2015-12-04 |
2018-08-10 |
시애틀 지네틱스, 인크. |
사차화 튜불리신 화합물들의 컨쥬게이트들
|
|
EP3419670A2
(en)
|
2016-02-26 |
2019-01-02 |
Regeneron Pharmaceuticals, Inc. |
Optimized transglutaminase site-specific antibody conjugation
|
|
US11767362B1
(en)
*
|
2016-03-15 |
2023-09-26 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
|
|
US20170326249A1
(en)
*
|
2016-05-10 |
2017-11-16 |
Bristol-Myers Squibb Company |
Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses
|
|
WO2018026742A1
(en)
*
|
2016-08-01 |
2018-02-08 |
Askgene Pharma Inc. |
Novel antibody-albumin-drug conjugates (aadc) and methods for using them
|
|
TWI851531B
(zh)
|
2016-08-09 |
2024-08-11 |
美商思進公司 |
具有改善之生理化學性質之具自我穩定連接子之藥物結合物
|
|
WO2019059411A1
(en)
*
|
2017-09-20 |
2019-03-28 |
Chugai Seiyaku Kabushiki Kaisha |
DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
|
|
US12478686B2
(en)
|
2018-12-12 |
2025-11-25 |
Bristol-Myers Squibb Company |
Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
|
|
CA3143519A1
(en)
*
|
2019-06-26 |
2020-12-30 |
Volker Schellenberger |
Cd3 antigen binding fragments and compositions comprising same
|
|
JP7725466B2
(ja)
*
|
2019-11-13 |
2025-08-19 |
アムニクス ファーマシューティカルズ， インコーポレイテッド |
バーコード化されたｘｔｅｎポリペプチドおよびその組成物、ならびにその作製および使用方法
|
|
EP4135665A2
(en)
*
|
2020-04-13 |
2023-02-22 |
Mantra Bio, Inc. |
Modular binding proteins for extracellular vesicles and uses thereof
|
|
CN116669772A
(zh)
*
|
2020-11-19 |
2023-08-29 |
艾迪健公司 |
Gpc3结合剂、其缀合物以及使用它们的方法
|
|
CN114685668B
(zh)
*
|
2020-12-28 |
2023-10-13 |
石药集团巨石生物制药有限公司 |
一种人gpc3单克隆抗体及其缀合物
|